CBT
REGN icon

Central Bank & Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Central Bank & Trust’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Buy
2,357
+8
+0.3% +$5.45K 0.21% 90
2026
Q1 		$1.81M Sell
2,349
-86
-4% -$65.8K 0.29% 77
2025
Q4 		$1.88M Sell
2,435
-164
-6% -$111K 0.29% 73
2025
Q3 		$1.46M Buy
2,599
+531
+26% +$300K 0.23% 89
2025
Q2 		$1.09M Sell
2,068
-64
-3% -$35.7K 0.18% 101
2025
Q1 		$1.35M Buy
2,132
+443
+26% +$305K 0.23% 90
2024
Q4 		$1.2M Sell
1,689
-259
-13% -$217K 0.18% 88
2024
Q3 		$2.05M Buy
1,948
+650
+50% +$723K 0.28% 71
2024
Q2 		$1.36M Sell
1,298
-78
-6% -$75.6K 0.19% 85
2024
Q1 		$1.32M Sell
1,376
-111
-7% -$106K 0.19% 85
2023
Q4 		$1.31M Sell
1,487
-95
-6% -$78.2K 0.2% 88
2023
Q3 		$1.3M Buy
1,582
+8
+0.5% +$6.29K 0.23% 83
2023
Q2 		$1.13M Sell
1,574
-33
-2% -$25.4K 0.19% 95
2023
Q1 		$1.32M Buy
1,607
+120
+8% +$90.5K 0.24% 82
2022
Q4 		$1.07M Sell
1,487
-34
-2% -$25.1K 0.2% 92
2022
Q3 		$1.05M Sell
1,521
-425
-22% -$267K 0.23% 87
2022
Q2 		$1.15M Sell
1,946
-558
-22% -$363K 0.23% 82
2022
Q1 		$1.75M Buy
2,504
+113
+5% +$71.5K 0.28% 73
2021
Q4 		$1.51M Buy
2,391
+120
+5% +$73.8K 0.23% 81
2021
Q3 		$1.37M Sell
2,271
-86
-4% -$53.4K 0.23% 85
2021
Q2 		$1.32M Sell
2,357
-1,086
-32% -$550K 0.21% 81
2021
Q1 		$1.63M Sell
3,443
-994
-22% -$484K 0.28% 75
2020
Q4 		$2.14M Sell
4,437
-3,437
-44% -$1.86M 0.37% 70
2020
Q3 		$4.41M Buy
7,874
+316
+4% +$192K 0.83% 41
2020
Q2 		$4.71M Buy
+7,558
New +$4.29M 0.93% 34
2019
Q3 		– Sell
-9
Closed -$3K – 299
2019
Q2 		$3K Sell
9
-11,082
-100% -$3.69M ﹤0.01% 255
2019
Q1 		$4.55M Buy
11,091
+721
+7% +$297K 1.02% 36
2018
Q4 		$3.87M Buy
+10,370
New +$3.8M 0.98% 32

Other funds holding REGN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Central Bank & Trust's REGN Position: Q2 2026 in Review

Central Bank & Trust increased its Regeneron Pharmaceuticals (REGN) stake by 0.34% in Q2 2026, buying an estimated $5.45K and bringing the position to 2,357 shares worth $1.47M. The position accounts for 0.21% of the portfolio, ranked #90.

Central Bank & Trust first reported a position in REGN in Q4 2018 and has held it in 28 quarters since. The position peaked at $4.71M in Q2 2020. 208 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Central Bank & Trust held 2,357 shares of Regeneron Pharmaceuticals worth $1.47M as of Q2 2026.
  • Central Bank & Trust bought 8 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $5.45K.
  • Regeneron Pharmaceuticals made up 0.21% of Central Bank & Trust's portfolio in Q2 2026, its #90 holding.
  • Central Bank & Trust first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 28 quarters since.
  • Central Bank & Trust's Regeneron Pharmaceuticals position peaked at $4.71M in Q2 2020.
  • 208 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Central Bank & Trust's 13F filing for Q2 2026, filed 17 Jul 2026.